Celastrol’s druggability, molecular targets, and nanocarrier delivery against chronic diseases

Announcing a new publication for Acta Materia Medica journal. Celastrol is an active compound from the root of Tripterygium wilfordii Hook F that shows great potential in the treatment of inflammation, cancer, neurodegeneration, diabetes, and obesity.

Zimvie mulls sale after takeover approaches: Bloomberg

Dive Brief: Zimvie is considering a sale and other options after receiving takeover approaches, Bloomberg reported Tuesday. Citing unnamed sources, the financial news publication said

June 26, 2024

CEB-01 by Cebiotex for Leiomyosarcoma: Likelihood of Approval

CEB-01 is under clinical development by Cebiotex and currently in Phase I for Leiomyosarcoma.

June 20, 2024

Commure to Acquire Augmedix in $139M All-Cash Deal – M&A

What You Should Know: – Augmedix (AUGX), a leader in AI-powered medical documentation and data solutions, is being acquired by healthcare technology provider Commure in

July 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.